Cabergoline treatment for a large macroprolactinoma throughout pregnancy

Journal of Obstetrics and Gynaecology

Volumn 17, Issue 4, 1997, Pages 375-376

  Jones, J ^a   Bashir, T ^a   Olney, J ^a   Wheatley, T ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ADULT; ARTICLE; CASE REPORT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; VISUAL FIELD;

EID: 0030859021     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443619750112916     Document Type: Article

References (3)

1. Bevan J. S., Webster J., Burke C. W. and Scanlon M. F. (1992) Dopamine agonists and pituitary tumor shrinkage. Endocrine Review, 13, 220-240.
2. Kupersmith M. J., Rosenberg C. and Kleinberg D. (1994) Visual loss in pregnant women with pituitary adenomas. Annals of Internal Medicine, 121, 473-477.
3. Webster J., Piscitelli G., Polli A., Ferrari C. J., Ismail I. and Scanlon M. F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhoea. New England Journal of Medicine, 331, 904-909.